TIME for a change in practice: insights from the TIME 1, 2, and 3 trials

Najib M. Rahman (Oxford, United Kingdom)

Source: International Congress 2017 – Malignant pleural effusion management in 2017: a review of recent RCTs
Session: Malignant pleural effusion management in 2017: a review of recent RCTs
Session type: Symposium
Number: 4804
Disease area: Thoracic oncology

WebcastSlide presentation

Rating: 5
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Najib M. Rahman (Oxford, United Kingdom). TIME for a change in practice: insights from the TIME 1, 2, and 3 trials. International Congress 2017 – Malignant pleural effusion management in 2017: a review of recent RCTs

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
What have we learned from big platform trials of COVID? RECOVERY, REMAP-CAP and others
Source: Virtual Congress 2021 – How science conquered COVID-19: from big platform trials to patients
Year: 2021


A self-management programme of activity coping and education (SPACE) for COPD: 6 week results from a randomised controlled trial
Source: Annual Congress 2012 - The best abstracts in chronic care
Year: 2012

"PROGRESSION OF SNORING AND OBSTRUCTIVE SLEEP APNOEA: THE ROLE OF INCREASING WEIGHT AND TIME". G. BERGER, R. BERGER AND A. OKSENBERG. EUR RESPIR J 2009; 33: 338-345.
Source: Eur Respir J 2009; 33: 947
Year: 2009


Session 1: The meaning of the words - General discussion
Source: Research Seminar 2021 – Lung function trajectories from birth to death, health and disease, and pre-war to today
Year: 2021

First demonstration of the good efficacy/safety ratio of Nicotinell® 1mg Lozenge (NL 1mg), a new form of nicotine substitution, by randomized clinical trial
Source: Eur Respir J 2001; 18: Suppl. 33, 12s
Year: 2001

"WHICH PATIENTS SHOULD BE TREATED WITH ANTI-IGE?". K-M. BEEH. EUR RESPIR REV 2007; 16: 104, 85 87.
Source: Eur Respir Rev 2007; 16: 211
Year: 2007


Reading list EW1-3-5
Source: Amsterdam 2015 - Educational material
Year: 2015

"ENVIRONMENTAL TEMPERATURE AND RELATIVE HUMIDITY INFLUENCE EXHALED BREATH CONDENSATE PH". T. KULLMANN, I. BARTA, B. ANTUS, M. VALYON AND I. HORVATH. EUR RESPIR J 2008; 31: 474-475.
Source: Eur Respir J 2008; 31: 912
Year: 2008


Handout EW1-3-5
Source: Amsterdam 2015 - Educational material
Year: 2015

Expression of claudins 1, 2, 3, 4, 5 and 7 in lung cancer
Source: Annual Congress 2009 - Lung cancer biology
Year: 2009


"TACROLIMUS FOR ANTISYNTHETASE SYNDROME WITH INTERSTITIAL LUNG DISEASE?" [REPLY LETTER]. L.P. NICOD. EUR RESPIR J 2008; 32: 245-246.
Source: Eur Respir J 2008; 32: 822
Year: 2008


BUDESONIDE/FORMOTEROL MAINTENANCE AND RELIEVER THERAPY: AN EFFECTIVE ASTHMA TREATMENT OPTION? EUR RESPIR J 2005; 26: 819-828.
Source: Eur Respir J 2005; 26: 1191
Year: 2005


EVOLUTION OF THE SEVERITY OF THE NICOTINE WITHDRAWAL SYNDROM (NWS) DEPENDING ON GENDER.
Source: Virtual Congress 2020 – From tobacco control policy to smoking cessation
Year: 2020


"CAN CAP GUIDELINE ADHERENCE IMPROVE PATIENT OUTCOME IN INTERNAL MEDICINE DEPARTMENTS?". F. BLASI, I. IORI, A. BULFONI, S. CORRAO, S. COSTANTINO AND D. LEGNANI. EUR RESPIR J 2008; 32: 902-910.
Source: Eur Respir J 2009; 33: 223
Year: 2009


NON-CYSTIC FIBROSIS (CF) BRONCHIECTASIS: A 5-YEAR RETROSPECTIVE STUDY WITH A FOCUS ON PATIENTS WITH PRIMARY IMMUNODEFICIENCIES (PID)
Source: International Congress 2018 – Management of bronchiectasis and large airway diseases
Year: 2018


General discussion: Day 2
Source: Course 2015 - Clinical exercise testing
Year: 2015

BT10+ study design: 10 year follow-up of subjects receiving bronchial thermoplasty (BT) in 3 randomized controlled studies
Source: International Congress 2017 – To freeze or heat?
Year: 2017